Heffter Research Institute

Committed to developing clinical protocals for entheogens

 

Description

Santa Fe, NM – EIN 850414512 heffter.org

The Heffter Research Institute was incorporated in New Mexico in 1993 as a non-profit scientific organization. Since its inception, Heffter has been helping to design, review, and fund the leading studies on psilocybin at prominent research institutions in the US and Europe. Our research has explored psilocybin for the treatment of cancer-related distress and addiction, for understanding the relationship between the psychedelic experience and spirituality, and for basic science research into the physiology of brain activity, cognition, and behavior. The Heffter Institute believes that psychedelics have great, unexplored potential that requires independently funded scientific research to find their best uses in medical treatment. We are not an endowed foundation, and so there is a continuous need for funding to support this critical research.

Wiki

Heffter Research Institute

Heffter Research Institute
Heffter Logo
Founded1993
Type501(c)(3) Nonprofit
FocusScientific research with psychedelic drugs
WebsiteHeffter Research Institute website

The Heffter Research Institute is a 501(c)(3) nonprofit organization that promotes research with classic hallucinogens and psychedelics, predominantly psilocybin, to contribute to a greater understanding of the mind and to alleviate suffering. Founded in 1993 as a virtual institute, Heffter primarily funds academic and clinical scientists and made more than $3.1 million in grants between 2011 and 2014.[1][2][3][4] Heffter's recent clinical studies have focused on psilocybin-assisted treatment for end-of-life anxiety and depression in cancer patients, as well as alcohol and nicotine addiction.

History

Arthur Heffter

Arthur Heffter was a German chemist/pharmacologist/physician who first isolated pure Mescaline from the peyote cactus in the late 1890s. He also proved that mescaline was the alkaloid in the cactus that is responsible for its psychoactive properties. This was the first psychedelic compound to be isolated and identified from its natural source, making Dr. Heffter the first scientist to study a pure psychedelic drug. Heffter's elucidation of the mescaline structure allowed it to be prepared by laboratory synthesis in 1919 by Ernst Späth, thus making it available to the wider scientific community.

Founding and history

The institute was founded in 1993 by David E. Nichols. Co-founders included Mark Geyer, Ph.D., George Greer, M.D., Charles Grob, M.D. and Dennis McKenna, Ph.D.

At the time, psychedelic research had been dormant for approximately 20 years and was not eligible to receive government funding, necessitating private funding to restart the field.[5] The institute was created to secure the private funding and to evaluate research projects for their scientific merit. The institute was incorporated as a nonprofit organization in New Mexico, and received its 501(c)(3) designation from the Internal Revenue Service in 1994.[6]

The first decade of research primarily focused on the mechanisms of action and effects of MDMA, along with clinical studies on ketamine treatment for Heroin addiction in Russia.[7][8] The institute also funded several small fellowships for young scientists.

Since the turn of the century, the institute's work has focused primarily on psilocybin, including funding the first psychedelic treatment study in the U.S. in decades, treating obsessive-compulsive disorder with psilocybin at the University of Arizona.[9] This study coincided with a number of neuroscience studies of psilocybin and a focus on treating anxiety and depression in cancer patients with psilocybin and addictions.

Organization (board and staff)

The current board of directors consists of seven scientists and five Philanthropists.[10] Dr. Nichols remains the president, with George Greer, M.D. as the medical director and Lynette Herring as the business manager.

Research publications

The institute has provided funding for more than 80 Scientific publications concerned with psychedelic drug research.[11]

Cancer distress

One supported research study found that a single dose of psilocybin significantly reduced anxiety and depressive symptoms in cancer patients.[12] The institute then funded two larger clinical trials of the same treatment at New York University and Johns Hopkins University, which is expected to be published in 2016.[13] Following that, the institute will be supporting an FDA Phase 3 study as a step toward gaining FDA approval of psilocybin for the treatment of anxiety and depression in cancer patients.

Addiction

Five scientific articles on Heffter-supported treatment of addictions with psilocybin have been published.[11] Two recent small pilot studies on alcohol and smoking addiction showed significant positive results.[14][15] As of early 2016, a large clinical trial is underway at New York University for alcohol dependence and at Johns Hopkins University for smoking.

Two earlier studies on the treatment of heroin addiction with ketamine also showed a significant benefit.[7][8]

Spirituality

Several Heffter-supported studies on Spiritual experiences and practices involving ayahuasca and psilocybin have been published.[11]

Neuroscience research

There have been more than 70 scientific publications resulting from Heffter-supported neuroscience research,[11] mostly from the at the University of Zurich, where one of the board members, Dr. Franz Vollenweider is the principal investigator.[16] One of these studies found that psilocybin inhibits the processing of negative emotions in the brain.[17]

See also

References

  1. ^ "Guidestar". Guidestar USA. May 2016.
  2. ^ "Guidestar" (PDF). Guidestar. January 2015. Retrieved May 2016. Check date values in: |access-date= (help)
  3. ^ "Guidestar" (PDF). January 2013. Retrieved May 2016. Check date values in: |access-date= (help)
  4. ^ "Guidestar" (PDF). January 2012. Retrieved May 2016. Check date values in: |access-date= (help)
  5. ^ Pollan, Michael (February 5, 2015). "New Yorker". The New Yorker.
  6. ^ Nichols, David E. (March 2014). "Journal of Psychoactive Drugs". Journal of Psychoactive Drugs. 46 (1): 20–26. doi:10.1080/02791072.2014.873688. PMID 24830182.
  7. ^ a b Krupitsky, E (December 2002). "Ketamine heroin 1". J Subst Abuse Treat. 23 (4): 273–83. doi:10.1016/s0740-5472(02)00275-1. PMID 12495789.
  8. ^ a b Krupitsky, EM (March 2007). "Ketamine heroin 2". J Psychoactive Drugs. 39 (1): 13–9. doi:10.1080/02791072.2007.10399860. PMID 17523581.
  9. ^ Moreno, FA (November 2006). "Psilocybin OCD". J Clin Psychiatry. 67 (11): 1735–40. doi:10.4088/jcp.v67n1110. PMID 17196053.
  10. ^ "Heffter Board". Heffter Research Institute. Retrieved June 2016. Check date values in: |access-date= (help)
  11. ^ a b c d "Heffter publications". Heffter Research Institute. Retrieved June 2016. Check date values in: |access-date= (help)
  12. ^ Grob, Charles S. (January 2011). "HUCLA psilocybin cancer". Archives of General Psychiatry. 68 (1): 71–8. doi:10.1001/archgenpsychiatry.2010.116. PMID 20819978.
  13. ^ Morin, Roc (April 2014). "Atlantic". The Atlantic.
  14. ^ Cortez, Michelle Fay (September 2014). "Bloomberg". Bloomberg News.
  15. ^ Shallow, Parvati (October 2014). "CBS". CBS News.
  16. ^ "Heffter Zürich". University of Zurich. Retrieved May 2016. Check date values in: |access-date= (help)
  17. ^ "Science Daily". Psilocybin inhibits the processing of negative emotions in the brain. May 2014.

External links

Videos

IRS data by ProPublica Nonprofit Explorer


HEFFTER RESEARCH INSTITUTE INC

SANTA FE, NM 87501-2835 | Tax-exempt since June 1998
  • EIN: 85-0414512
  • Classification (NTEE)
    Unknown (U00Z) (Science and Technology Research Institutes, Services)
  • Nonprofit Tax Code Designation: 501(c)(3)
    Defined as: Organizations for any of the following purposes: religious, educational, charitable, scientific, literary, testing for public safety, fostering national or international amateur sports competition (as long as it doesn’t provide athletic facilities or equipment), or the prevention of cruelty to children or animals.
  • Donations to this organization are tax deductible.
Fiscal year ending

Dec. 2018

Fiscal year ending Dec.

2018

PDF

990
990

Full Text

990 (filed on Aug. 27, 2020)

Full Filing

990 (filed on Jan. 21, 2020)

Full Filing

Raw XML

Form 990 documents available

Extracted filing data is not available for this tax period, but Form 990 documents are available for download.

Fiscal year ending

Dec. 2017

Fiscal year ending Dec.

2017

Full Text

990 (filed on Nov. 7, 2018)

Full Filing

Raw XML

990

Total Revenue

$732,335

Total Functional Expenses $1,132,186
Net income -$399,851
Notable sources of revenue Percent of total revenue
Contributions $731,880 99.9%
Program services $0
Investment income $772 0.1%
Bond proceeds $0
Royalties $0
Rental property income $0
Net fundraising $0
Sales of assets -$317
Net inventory sales $0
Other revenue $0
Notable expenses Percent of total expenses
Executive compensation $70,740 6.2%
Professional fundraising fees $0
Other salaries and wages $0
Other
Total Assets $506,832
Total Liabilities $249,378
Net Assets $257,454
Fiscal year ending

Dec. 2016

Fiscal year ending Dec.

2016

Full Text

990 (filed on Aug. 23, 2017)

Full Filing

Raw XML

990

Total Revenue

$1,749,885

Total Functional Expenses $1,387,607
Net income $362,278
Notable sources of revenue Percent of total revenue
Contributions $1,749,356 100.0%
Program services $0
Investment income $131 0.0%
Bond proceeds $0
Royalties $0
Rental property income $0
Net fundraising $0
Sales of assets $398 0.0%
Net inventory sales $0
Other revenue $0
Notable expenses Percent of total expenses
Executive compensation $63,120 4.5%
Professional fundraising fees $0
Other salaries and wages $0
Other
Total Assets $852,866
Total Liabilities $195,561
Net Assets $657,305
Fiscal year ending

Dec. 2015

Fiscal year ending Dec.

2015

PDF

990

Full Text

990 (filed on Sept. 8, 2016)

Full Filing

Raw XML

990

Total Revenue

$950,998

Total Functional Expenses $1,339,543
Net income -$388,545
Notable sources of revenue Percent of total revenue
Contributions $950,652 100.0%
Program services $0
Investment income $277 0.0%
Bond proceeds $0
Royalties $0
Rental property income $0
Net fundraising $0
Sales of assets $69 0.0%
Net inventory sales $0
Other revenue $0
Notable expenses Percent of total expenses
Executive compensation $36,780 2.7%
Professional fundraising fees $0
Other salaries and wages $0
Other
Total Assets $406,997
Total Liabilities $111,970
Net Assets $295,027
Fiscal year ending

Dec. 2014

Fiscal year ending Dec.

2014

PDF

990

Full Text

990 (filed on July 7, 2015)

Full Filing

Raw XML

990

Total Revenue

$1,474,149

Total Functional Expenses $1,022,209
Net income $451,940
Notable sources of revenue Percent of total revenue
Contributions $1,471,787 99.8%
Program services $0
Investment income $81 0.0%
Bond proceeds $0
Royalties $0
Rental property income $0
Net fundraising $0
Sales of assets $2,281 0.2%
Net inventory sales $0
Other revenue $0
Notable expenses Percent of total expenses
Executive compensation $35,323 3.5%
Professional fundraising fees $0
Other salaries and wages $0
Other
Total Assets $685,656
Total Liabilities $2,084
Net Assets $683,572
Fiscal year ending

Dec. 2013

Fiscal year ending Dec.

2013

PDF

990

Full Text

990 (filed on Oct. 28, 2014)

Full Filing

Raw XML

990

Total Revenue

$637,514

Total Functional Expenses $1,205,894
Net income -$568,380
Notable sources of revenue Percent of total revenue
Contributions $658,756 Over 100%
Program services $0
Investment income $327 0.1%
Bond proceeds $0
Royalties $0
Rental property income $0
Net fundraising -$21,700
Sales of assets $131 0.0%
Net inventory sales $0
Other revenue $0
Notable expenses Percent of total expenses
Executive compensation $22,800 1.9%
Professional fundraising fees $0
Other salaries and wages $0
Other
Total Assets $262,392
Total Liabilities $30,760
Net Assets $231,632
Fiscal year ending

Dec. 2012

Fiscal year ending Dec.

2012

PDF

990

Raw XML

990

Total Revenue

$1,413,894

Total Functional Expenses $874,098
Net income $539,796
Notable sources of revenue Percent of total revenue
Contributions $1,413,943 Over 100%
Program services $10 0.0%
Investment income $57 0.0%
Bond proceeds $0
Royalties $0
Rental property income $0
Net fundraising $0
Sales of assets -$116
Net inventory sales $0
Other revenue $0
Notable expenses Percent of total expenses
Executive compensation $12,005 1.4%
Professional fundraising fees $4,467 0.5%
Other salaries and wages $0
Other
Total Assets $800,012
Total Liabilities $0
Net Assets $800,012
Fiscal year ending

Dec. 2011

Fiscal year ending Dec.

2011

PDF

990

Total Revenue

$357,741

Total Functional Expenses $411,995
Net income -$54,254
Notable sources of revenue Percent of total revenue
Contributions $354,239 99.0%
Program services $0
Investment income $66 0.0%
Bond proceeds $0
Royalties $0
Rental property income $0
Net fundraising $0
Sales of assets $3,436 1.0%
Net inventory sales $0
Other revenue $0
Notable expenses Percent of total expenses
Executive compensation $5,077 1.2%
Professional fundraising fees $0
Other salaries and wages $0
Other
Total Assets $260,216
Total Liabilities $0
Net Assets $260,216
Fiscal year ending

Dec. 2010

Fiscal year ending Dec.

2010

PDF

990

Form 990 documents available

Extracted filing data is not available for this tax period, but Form 990 documents are available for download.

Fiscal year ending

Dec. 2009

Fiscal year ending Dec.

2009

PDF

990-EZ
990-EZ

Form 990 documents available

Extracted filing data is not available for this tax period, but Form 990 documents are available for download.

Fiscal year ending

Dec. 2008

Fiscal year ending Dec.

2008

PDF

990-EZ

Form 990 documents available

Extracted filing data is not available for this tax period, but Form 990 documents are available for download.

Fiscal year ending

Dec. 2007

Fiscal year ending Dec.

2007

PDF

990

Form 990 documents available

Extracted filing data is not available for this tax period, but Form 990 documents are available for download.

Fiscal year ending

Dec. 2005

Fiscal year ending Dec.

2005

PDF

990

Form 990 documents available

Extracted filing data is not available for this tax period, but Form 990 documents are available for download.

Fiscal year ending

Dec. 2004

Fiscal year ending Dec.

2004

PDF

990

Form 990 documents available

Extracted filing data is not available for this tax period, but Form 990 documents are available for download.

Fiscal year ending

Dec. 2003

Fiscal year ending Dec.

2003

PDF

990

Form 990 documents available

Extracted filing data is not available for this tax period, but Form 990 documents are available for download.

Fiscal year ending

Dec. 2002

Fiscal year ending Dec.

2002

PDF

990

Form 990 documents available

Extracted filing data is not available for this tax period, but Form 990 documents are available for download.

Fiscal year ending

Dec. 2001

Fiscal year ending Dec.

2001

PDF

990

Form 990 documents available

Extracted filing data is not available for this tax period, but Form 990 documents are available for download.


Last Updated: 2020-11-24 08:05